SUMMIT THERAPEUTICS INC (SMMT)
US86627T1088 - Common Stock
We assign a fundamental rating of 1 out of 10 to SMMT. SMMT was compared to 588 industry peers in the Biotechnology industry. SMMT has a bad profitability rating. Also its financial health evaluation is rather negative. SMMT does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
SMMT had negative earnings in the past year.
In the past year SMMT has reported a negative cash flow from operations.
SMMT had negative earnings in 4 of the past 5 years.
In the past 5 years SMMT always reported negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -303.00%, SMMT is doing worse than 94.20% of the companies in the same industry.
SMMT has a worse Return On Equity (-791.50%) than 81.91% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -303% | ||
| ROE | -791.5% | ||
| ROIC | N/A |
ROA(3y)-131%
ROA(5y)-86.39%
ROE(3y)-320.01%
ROE(5y)-201.72%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
SMMT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
SMMT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SMMT has been increased compared to 1 year ago.
SMMT has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, SMMT has an improved debt to assets ratio.
2.2 Solvency
SMMT has an Altman-Z score of -2.55. This is a bad value and indicates that SMMT is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -2.55, SMMT is in line with its industry, outperforming 46.93% of the companies in the same industry.
A Debt/Equity ratio of 1.29 is on the high side and indicates that SMMT has dependencies on debt financing.
SMMT has a worse Debt to Equity ratio (1.29) than 79.69% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.29 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.55 |
ROIC/WACCN/A
WACC8.61%
2.3 Liquidity
SMMT has a Current Ratio of 9.30. This indicates that SMMT is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of SMMT (9.30) is better than 78.50% of its industry peers.
A Quick Ratio of 9.30 indicates that SMMT has no problem at all paying its short term obligations.
SMMT has a better Quick ratio (9.30) than 78.84% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 9.3 | ||
| Quick Ratio | 9.3 |
3. Growth
3.1 Past
The earnings per share for SMMT have decreased strongly by -143.27% in the last year.
Looking at the last year, SMMT shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)-143.27%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q42.86%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A
3.2 Future
Based on estimates for the next years, SMMT will show a very negative growth in Earnings Per Share. The EPS will decrease by -40.74% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-63.2%
EPS Next 2Y-40.43%
EPS Next 3Y-40.74%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
SMMT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SMMT. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
SMMT's earnings are expected to decrease with -40.74% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-40.43%
EPS Next 3Y-40.74%
5. Dividend
5.1 Amount
SMMT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SUMMIT THERAPEUTICS INC
NASDAQ:SMMT (5/1/2024, 7:22:51 PM)
After market: 4.65 -0.05 (-1.06%)4.7
+0.77 (+19.59%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap3.30B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -303% | ||
| ROE | -791.5% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.29 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 9.3 | ||
| Quick Ratio | 9.3 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-143.27%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-63.2%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y